登录    
  
首页 > 期刊论文 > 论文摘要
Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系
         
The relationship between EGFR gene mutation and the expressions of ERCC1 and RRM1 proteins in stagesⅠ-Ⅲ lung adenocarcinoma tissues

摘    要
探讨Ⅰ~Ⅲ期肺腺癌组织中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变与切除修复交叉互补蛋白1(excision repair cross-complementation group 1,ERCC1)和核苷酸还原酶亚单位M1(ribonucleotide reductase subunit M1,RRM1)蛋白表达的关系。方法:应用扩增阻滞突变系统在荧光定量PCR仪上检测99例Ⅰ~Ⅲ期肺腺癌组织中EGFR基因19和21外显子的突变情况,应用免疫组织化学法检测其ERCC1和RRM1蛋白的表达。结果:肺腺癌患者中EGFR基因突变率为46.5%,在女性和不吸烟患者中较高(P<0.05);ERCC1蛋白高表达患者50例(50.5%),RRM1蛋白高表达患者52例(52.5%)。与未检测到EGFR基因突变的肺腺癌患者比较,EGFR基因突变患者ERCC1蛋白低表达者多见(P=0.035);肺腺癌组织中,EGFR基因突变与RRM1蛋白表达水平无关(P>0.05);ERCC1蛋白表达水平与RRM1蛋白表达水平无关(P>0.05)。结论:肺腺癌组织中EGFR突变者ERCC1蛋白倾向低表达,这类患者可能更能从以铂类为基础的化疗中受益。
标    签 肺肿瘤   受体,表皮生长因子   突变   切除修复交叉互补蛋白1   核苷酸还原酶亚单位M1   Lung neoplasms   Receptor, epidermal growth factor   Mutation   Excision repair cross-complementation group 1   Ribonucleotide reductase subunit M1  
 
Abstract
To investigate the relationship between the mutation of EGFR (epidermal growth factor receptor) gene and the expressions of ERCC1 (excision repair cross-complementation group 1) and RRM1 (ribonucleotide reductase M1) proteins in adenocarcinoma tissues from patients with stages Ⅰ-Ⅲ lung adenocarcinoma. Methods: The status of EGFR gene mutation in exons 19 and 21 in adenocarcinoma tissues from 99 patients with stages Ⅰ-Ⅲ lung adenocarcinoma was detected by amplification refractory mutation system using fluorescence-based quantitative-PCR instrument. The expressions of ERCC1 and RRM1 proteins were detected by immunohistochemistry. Results: The mutation rate of EGFR gene in all patients was 46.5%. The females or the non-smokers had a higher mutation rate of EGFR gene (P < 0.05). A high expression level of ERCC1 protein was found in 50.5% of patients (50/99), and a high expression level of RRM1 protein was also found in 52.5% of patients (52/99). A low expression level of ERCC1 protein was more likely to be seen in patients with EGFR mutation as compared with the patients without EGFR mutation (P = 0.035), but there was no significant relationship between EGFR mutation and the expression level of RRM1 protein (P > 0.05). There was also no relationship between the expressions of ERCC1 and RRM1 proteins (P > 0.05). Conclusion: A low level of ERCC1 protein is more likely to be expressed in lung adenocarcinoma patients with EGFR mutation, who may benefit from the platinum-based chemotherapy.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2013.03.009

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床研究

基金项目

收稿日期 2012/11/30

修改稿日期 2013/1/21

网络出版日期

作者单位点击查看


引用该论文: YAO Chuan-shan,MA Lei,LIU Rui-qing,LI Xing-ya. The relationship between EGFR gene mutation and the expressions of ERCC1 and RRM1 proteins in stagesⅠ-Ⅲ lung adenocarcinoma tissues[J]. Tumor, 2013, 33(3): 258~263
姚传山,马磊,刘瑞青,李醒亚. Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系[J]. 肿瘤, 2013, 33(3): 258~263


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】JEMAL A, SIEGEL R, XU J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5):277-300.
 
【2】HERBST R S. Review of epidermal growth factor receptor biology[J]. Int J Radiat Oncol Biol Phys, 2004, 59(2 Suppl):21-26.
 
【3】CHAN S K, GULLICK W J, HILL M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer—search and destroy[J]. Eur J Cancer, 2006, 42(1):17-23.
 
【4】SIMON G R, ISMAIL-KHAN R, BEPLER G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality[J]. Int J Biochem Cell Biol, 2007, 39(7-8):1318-1328.
 
【5】SU C, ZHOU S, ZHANG L, REN S, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer[J]. Med Oncol, 2011, 28(4):1411-1417.
 
【6】MOK T S, WU Y L, THONGPRASERT S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957.
 
【7】OLAUSSEN K A, DUNANT A, FOURET P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10):983-991.
 
【8】BEPLER G, KUSMARTSEVA I, SHARMA S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer[J]. J Clin Oncol, 2006, 24(29):4731-4737.
 
【9】任睿欣, 李嘉瑜, 李雪飞, 等. 扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变[J]. 肿瘤, 2012, 32(11):929-935.
 
【10】LEE K H,MIN H S,HAN S W,et al.ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer[J]. Lung Cancer, 2008, 60(3):401-407.
 
【11】PAO W,MILLER V,ZAKOWSKI M,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J]. Proc Natl Acad Sci U S A, 2004, 101(36):13306-13311.
 
【12】PAEZ J G, J.NNE P A, LEE J C, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676):1497-1500.
 
【13】邓秋华, 邱 源, 莫明聪, 等. 非小细胞肺癌表皮生长因子受体基因拷贝数与核苷酸切除修复交叉互补基因1和乳腺癌易感基因1的表达及其相关性分析[J]. 中华肿瘤杂志, 2011, 33(7):508-512.
 
【14】PESTA M, KULDA V, FIALA O, et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer[J]. Anticancer Res, 2012, 32(11):5003-5010.
 
【15】林肖鹰, 陈小岩, 陈志忠. 非小细胞肺癌组织ERCC1和RRM1表达及其临床预后的相关性研究[J]. 福建医科大学学报, 2011, 45(1):10-13.
 
【16】GANDARA D R, GRIMMINGER P, MACK P C, et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer[J]. J Thorac Oncol, 2010, 5(12):1933-1938.
 
【17】MITSUDOMI T, MORITA S, YATABE Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2):121-128.
 
【18】LI L, WANG H, YANG ES, et al. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells[J]. Cancer Res, 2008, 68(22):9141-9146.
 
【19】REYNOLDS C, OBASAJU C, SCHELL M J, et al. Randomized phase Ⅲ trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(34):5808-5815.
 
【20】林 莉, 刘晓晴, 王伟霞, 等. 实时荧光定量-PCR法检测6种肺癌细胞系中吉西他滨耐药相关基因的表达[J]. 肿瘤, 2008, 28(3):228-231.
 
【21】SIMON G R, SCHELL M J, BEGUM M, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced non small cell lung cancer: evidence from an individual patient analysis[J]. Cancer, 2012, 118(9):2525-2531.
 
【22】陈 芹, 周彩存, 张 颉. ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J]. 肿瘤, 2007, 27(9):719-722.
 
相关信息
   标题 相关频次
 Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系
 18
 Ⅰ期肺腺癌新分类组织亚型与EGFR突变的关系
 4
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 4
 肺癌细胞转化生长因子信息传递通路功能状态研究
 4
 肺癌中FHIT基因异常甲基化及其蛋白表达的意义
 3
 肺腺癌组织EGFR外显子19基因突变的实时定量PCR检测
 3
 晚期肺癌血清游离DNA中EGFR外显子19的基因突变研究
 3
 中国肺腺癌患者上皮生长因子受体基因突变的研究
 3
 Livin基因反义寡核苷酸诱导肺腺癌A549细胞的凋亡
 2
 MKK4基因启动子区遗传变异与中国南方人群肺癌易感性的相关性研究
 2
 SEMA3B基因在肺癌组织中的表达及其与p53表达、肿瘤血管新生的关系
 2
 survivin mRNA及蛋白在肺癌组织芯片中的表达及意义
 2
 UHRF1基因沉默可促进人肺腺癌A549细胞的凋亡
 2
 125I粒子不同放射剂量治疗癌性气道狭窄
 2
 18F-FDG肿瘤代谢显像结合血清肿瘤标志物检测鉴别肺部良恶性肿块
 2
 99mTc-depreotide与人肺腺癌A549细胞生长抑素受体结合实验
 2
 99m锝-甲氧基异丁基异腈在人肺癌细胞中的摄取与肺癌细胞耐药间的关系及二氯乙酸盐对肺癌细胞耐药的影响
 2
 18F-FDG双探头符合线路SPECT在肺癌诊断中的价值
 2
 1992—2012年天津市河西区肺癌发病状况和时间趋势分析
 2
 2002-2005年上海市15~44岁青年人肺癌发病的时间趋势、现况及生存期分析
 2
 2009年恶性肿瘤临床治疗新进展
 2
 2-DG对肺腺癌A549细胞增殖的影响及其相关机制
 2
 3株肺癌细胞中9个肿瘤相关基因的启动子甲基化状态和部分基因表达的相关性(英文)
 2
 40例肺癌心包积液的治疗及预后
 2
 41例大肠癌组织APC基因突变检测
 2
 Ⅳ型胶原对耐顺铂人肺腺癌细胞化疗诱导凋亡的影响
 2
 A549肺癌细胞球抗凋亡能力及耐药蛋白表达分析
 2
 ANGPTL4基因及缺失突变体对肝癌细胞生长的影响
 2
 BAG-1蛋白在衣霉素诱导人肺癌A549细胞内质网应激及提高顺铂敏感性中的作用
 2
 CD147对肺癌A549细胞增殖、迁移和侵袭的影响
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2